Vaccination against enteric pathogens: From science to vaccine trials

Current Opinion in Microbiology

Volumn 1, Issue 1, 1998, Pages 116-124

  Lindberg, Alf A ^a  

^a Pasteur Merieux Connaught   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SHIGELLA;

BACTERIAL VACCINE; DNA VACCINE; VIRUS VACCINE;

CLINICAL TRIAL; GASTROENTERITIS; GRAM NEGATIVE FACULTATIVELY ANAEROBIC RODS; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; REVIEW; ROTAVIRUS; VACCINATION; VIROLOGY; VIRULENCE; VIRUS INFECTION;

BACTERIAL VACCINES; CLINICAL TRIALS; GASTROENTERITIS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS; HUMANS; ROTAVIRUS; ROTAVIRUS INFECTIONS; VACCINATION; VACCINES, DNA; VIRAL VACCINES; VIRULENCE;

EID: 0031988013     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(98)80151-3     Document Type: Article

References (35)

1. Kiyono HS, Ogra PL, McGhee JR (Eds): Mucosal vaccines. San Diego: Academic Press; 1996. Contains several excellent reviews regarding vaccines against enteric pathogens.
2. Phalipon A, Kaufman M, Michetti P, Cavaillon JM, Huerre M, Sansonetti PJ, Kraehenbul JP: Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis. J Exp Med 1995, 182:769-778.
3. Cohen D, Askenazi S, Green M, Lerman Y, Slepon R; Robin G, Orr N, Taylor DN, Sadoff JC, Chu C et al.: Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun 1996, 64:4074-4077.
4. Velucchi M, Rustici A, Meazza C, Villa P, Ghezzi P, Tsai CM, Porro M: A model of Neisseria meningitidis vaccine based on LPS micelles detoxified by synthetic endotoxin peptides. J Endotox Res 1997, 4:261-272.
5. VanLoon FPL, Clemens JD, Chakraborty J, Rao MR, Kay BA, Sack DA, Yunus MD, Ali MD, Svennerholm AM, Holmgren J: Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years follow-up. Vaccine 1996, 14:162-166.
6. Douce G, Turcotte C, Cropley I, Roberts M, Pizza MG, Domenighini D, Rappuoli R, Dougan G: Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxin mucosal adjuvants. Proc Natl Acad Sci USA 1995, 92:1644-1648.
7. Midthun K, Kapikian AZ: Rotavirus vaccines: an overview. Clin Microbiol Rev 1996, 9:423-434.
8. Joensuu J, Koshenniemi E, Pang XL, Vesikari T: A randomised, double-blind, placebo controlled trial of rhesus human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997, 350:1205-1209. Provides clinical data of protective efficacy of rhesus reassortant rotavirus vaccine.
9. Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM, Gonzalez R, Cunto W, Hoshino Y, Kapikian AZ: Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. New Engl J Med 1997, 337:1181-1187.
10. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg H: Protective effect of Rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996, 272:104-107. Shows that IgA antibodies administered in the circulation, but not given in the intestine, protect against experimental mouse rotavirus infection.
11. Ball JM, Tian P, Zeng CQ-Y, Morris AP, Estes MK: Age dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 1996, 272:101-104. Provides evidence that a nonstructural rotavirus protein may function as an enterotoxin.
12. Ward RL, Mason BA, Bernstein DI, Sander DS, Smith VE, Zandle GA, Rappaport RS: Attenuation of a human rotavirus vaccine candidate did not correlate with mutations in the NSP4 protein gene. J Virol 1997, 71:6267-6270.
13. Conner ME, Zsarley CD, Hu B, Parsons S, Drabinski D, Greiner S, Smith R, Jiang B, Corsaro B, Barniak V et al.: Virus-like particles as a rotavirus subunit vaccine. J Infect Dis 1996, 174(suppl 1):S88-S92.
14. Herrmann JE, Chen SC, Fynan EF, Santoro JC, Greenberg HB, Wang S, Robinson HL: Protection against rotavirus infections by DNA vaccination. J Infect Dis 1996, 174(suppl 1):S93-S97. DNA immunization with genes coding for three structural rotavirus proteins protects against experimental mouse rotavirus infection.
15. Sato Y, Roman M, Tighe H, Lee D, Corr M, Dguyen MD, Silverman GF, Lotz M, Carson DA, Raz E: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273:352-354. Nucleotide sequences upregulate the immune system.
16. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997, 3:849-854.
17. Noriega F, Formal SB, Kotloff KL, Lindberg AA: Vaccines against Shigella infections Part ii: engineered attenuated mutants of Shigella as live oral vaccines. In New Generation Vaccines, edn 2. Edited by Levine MM, Woodrow Gc, Kaper JB, Cobon GS. New York: Marcel Dekker, Inc; 1997:853.
18. Fasano A, Noriega FR, Maneval DR Jr, Chanasongeram S, Russell R, Guandalini S, Levine MM: Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest 1995, 6:2853-2861.
19. Nataro JP, Seriwatana J, Fasano A, Maneval DR, Guers LD, Noriega F, Dubovsky F, Levine MM, Morris JG Jr: Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun 1995, 63:4721-4728.
20. Mounier J, Bahrani FK, Sansonetti PJ: Secretion of Shigella flexneri Ipa invasins on contact with epithelial cells and subsequent entry of the bacterium into cells are growth stage dependent. Infect Immun 1997, 65:774-782.
21. De Geyler C, Vogt B, Benjelloun-Touimi Z, Sansonetti PJ, Ruysschaert JM, Parsot C, Cabiaux V: Purification of IpaC, a protein involved in entry of Shigella flexneri into epithelial cells and characterization of its interaction with lipid membranes. FEBS Lett 1997, 400:149-154. Dissects the mode of entry of Shigella into epithelial cells.
22. Egile C, D'Hauteville H, Parsot C, Sansonetti PJ: SopA, the outer membrane protease responsible for polar localization of IcsA in Shigella flexneri. Mol Microbiol 1997, 23:1063-1073.
23. Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I et al.: Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997, 349:155-159. Provides evidence that serum antibodies may protect against shigellosis.
24. Levine MM, Sztein MB: Human mucosal vaccines for Salmonella typhi infections. In Mucosal vaccines. Edited by Kiyono H, Ogra PL, McGhee JR. San Diego: Academic Press; 1996:201-211.
25. Levine MM, Galen J, Barry E, Noriega F, Chatfield S, Sztein M, Dougan G, Tacket C: Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J Biotech 1996, 44:193-196.
26. Chatfield SN, Roberts M, Dougan G, Hormaeche C, Khan CMA: The development of oral vaccines against parasitic diseases utilizing live attenuated Salmonella. Parasitology 1995, 110:S17-S24.
27. Holmgren J, Svennerholm AM: Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. In Mucosal Vaccines. Edited by Kiyono H, Ogra PL, McGhee JR. San Diego: Academic Press; 1996:241-253.
28. Sommerfelt H, Steinsland H, Grewal HMS, Viboud GI, Bhandari N, Gaastra W, Svernnerholm AM, Bhan MJ: Colonization factors of enterotoxigenic Escherichia coli isolated from children in North India. J infect Dis 1996 174:768-776.
29. Jertborn M, Svennerholm AM, Holmgren J: Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit - O1/O139 whole cell cholera vaccine. Vaccine 1996, 14: 1459-1465.
30. Taylor DN, Tacket CO, Losonsky G, Castro O, Gutierrez J, Meza R, Nataro JP, Kaper JB, Wasserman SS, Edelman R et al.: Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect Immun 1997, 65:3852-3856.
31. World Health Organization: Global programme for vaccines and immunization. In Vaccine research and develpment: report of technical review group meeting: 1997 June 9-10; Geneva.
32. Ulmer JB, Donnelly JJ, Shiver JW, Liu MA: Prospects for induction of mucosal immunity by DNA vaccines. In Mucosal Vaccines. Edited by Kiyono H, Ogra PL, McGhee JR. San Diego: Academic Press; 1996:119-127.
33. Etchart N, Buckland R, Liu MA, Wild TF, Kaiserlian D: Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol 1997, 78:1577-1580.
34. Jouanguy E, Altare F, Lamhamedi S, Revi P, Newport M, Levine M, Blanche S, Fischer A, Casanova JL: Interferon gamma receptor deficiency associated with idiopathic lethal bacillus Calmette-Guérin (BCG) infection. New Engl J Med 1997, in press.
35. Tacket O, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, Pickard D, Dougan G, Chatfield SN, Levine MM: Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroCaroD and immune response in humans. Infect Immun 1997, 65:452-456. First evidence of a live attenuated typhoid vaccine that is both safe and immunogenic in a single oral dose.